## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing Of Claims**

- 1. (Currently amended) A composition comprising a protein in crystalline form wherein the protein has at least 90% identity with residues 605-883 of SEQ. ID No. 1. consists of SEQ ID NO: 3.
- 2. (Currently amended) A composition according to claim 1 wherein the protein has at least 95% identity with residues 605-883 of SEQ. ID No. 1. is present in the protein crystal as a dimer.
- 3. (Cancelled)
- 4. (Currently amended) A composition according to claim 1 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution <u>having a value less</u> greater-than 3.0 Angstroms.
- 5. (Original) A composition according to claim 1 wherein the protein crystal has a crystal lattice in a P3<sub>2</sub>21 space group.
- 6. (Original) A composition according to claim 1 wherein the protein crystal has a crystal lattice having unit cell dimensions, +/- 5%, of a=72.12Å, b= 72.12Å and c=241.62Å.
- 7. (Cancelled)
- 8. (Cancelled)
- 9. (Currently amended) A method for forming a crystal of a protein comprising:

U.S. Application Serial No. 10/601,324 Office Action mailed April 10, 2006 Response to Office Action dated July 7, 2006

forming a crystallization volume comprising[[:]] a precipitant solution and a protein wherein the protein has at least 90% identity with residues 605-883 of SEQ. ID No. 1; and that consists of SEQ ID NO: 3; and

storing the crystallization volume under conditions suitable for crystal formation of the protein.

forming a crystalline form of the protein in the crystallization volume.

- 10. (Currently amended) A method according to claim 9 wherein the protein has at least 95% identity with residues 605-883 of SEQ. ID No. 1. is present in the protein crystal as a dimer.
- 11. (Cancelled)
- 12. (Currently amended) A method according to claim 9 wherein the protein <u>crystal</u> diffracts X-rays for a determination of structure coordinates to a resolution <u>having a value less</u> greater-than 3.0 Angstroms.
- 13. (Original) A method according to claim 9 wherein the protein crystal has a crystal lattice in a P3<sub>2</sub>21 space group.
- 14. (Original) A method according to claim 9 wherein the protein crystal has a crystal lattice having unit cell dimensions, +/- 5%, of a=72.12Å, b= 72.12Å and c=241.62Å.
- 15. (Currently amended) A method according to claim 9, the method further comprising: diffracting the protein crystal to produce a diffraction pattern; and solving the structure of the protein from the diffraction pattern.
- 16. (Cancelled)
- 17. (Currently amended) A composition comprising an isolated a protein consisting of SEQ. ID-No. 3. SEQ ID NO: 3.
- 18-25. (Cancelled)

- 26. (New) A method according to claim 15, the method further comprising: performing rational drug design using the solved structure; and identifying an entity that associates with the protein.
- 27. (New) A method according to claim 26 wherein the protein is present in the protein crystal as a dimer.
- 28. (New) A method according to claim 26 wherein the protein crystal has a crystal lattice having unit cell dimensions, +/- 5%, of a=72.12Å, b= 72.12Å and c=241.62Å.
- 29. (New) A method according to claim 26 wherein the protein crystal has a crystal lattice in a P3<sub>2</sub>21 space group.
- 30. (New) A method according to claim 26, the method further comprising: selecting one or more entities based on the rational drug design; and contacting the selected entities with the protein.
- 31. (New) A method according to claim 26, the method further comprising measuring an activity of the protein when contacted with the one or more entities.
- 32. (New) A method according to claim 26, the method further comprising:
  comparing activity of the protein in a presence of and in the absence of the one or more entities; and

selecting entities where activity of the protein changes depending whether a particular entity is present.

33. (New) A method according to claim 26, the method further comprising: contacting cells expressing the protein with the one or more entities; and detecting a change in a phenotype of the cells when a particular entity is present.